相关实验视频

Updated: Sep 20, 2025

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

氨酸丰富的重复激酶2生物标志物用于帕金森病

Nicolas Dzamko¹

¹Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.

The Biochemical journal

|May 29, 2025

概括

在帕金森病 (PD) 研究中,需要生物标志物来跟踪氨酸丰富的重复激酶2 (LRRK2) 功能. 本综述涵盖了对LRRK2生物标志物的最新发现,用于治疗开发和了解PD进展.

科学领域:

神经科学是一个神经科学.
生物化学生物化学

背景情况:

氨酸丰富的重复激酶2 (LRRK2) 是帕金森病 (PD) 的关键治疗标.
临床前模型表明LRRK2疗法可以改善PD中的细胞功能障碍.
针对LRRK2的小分子和反意义寡核酸正在临床试验中.

研究的目的:

审查最近关于白丰富重复激酶2 (LRRK2) 的生物标志物的发现.
突出需要生物标志物来监测LRRK2治疗反应和PD进展.
讨论生物标志物,以识别更广泛的PD人群中增加的LRRK2水平/活性.

主要方法:

关于LRRK2生物标志物的最新研究的文献综述.
对针对LRRK2的当前治疗策略的分析2.
综合了关于LRRK2在帕金森病发病过程中的作用的数据.

主要成果:

LRRK2激酶抑制剂和反感性寡核化物正在为PD进行临床研究.
对于LRRK2在PD病变发生过程中的作用的明确理解仍然缺乏.
对于临床应用,需要用于跟踪LRRK2功能的最终生物标志物.

结论:

生物标志物对于评估帕金森病中的LRRK2向疗法至关重要.
除了致病突变之外,识别生物标志物可以扩大治疗范围.
对LRRK2生物标志物的进一步研究将促进PD治疗策略的发展.

关键词:

这是LRRK2 拉布拉布GTPase可以使用.生物标志物生物标志物 lysosome 溶解酶体是如何形成的线粒体中的线粒体.

更多相关视频

Assaying the Kinase Activity of LRRK2 in vitro

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

相关概念视频

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...